Again, based on preclinical data, expectations that BETi would show efficacy against these tumours were high and, consequently, the first published clinical trial using BETi was focused on NMC.114 In this trial, a small series of four patients carrying diverse, advanced-stage tumours harbouring BRD4–NUT fusions received OTX015. This evidence concerns the gene BRD4 and nut midline carcinoma.